JP2015218166A5 - - Google Patents

Download PDF

Info

Publication number
JP2015218166A5
JP2015218166A5 JP2015097829A JP2015097829A JP2015218166A5 JP 2015218166 A5 JP2015218166 A5 JP 2015218166A5 JP 2015097829 A JP2015097829 A JP 2015097829A JP 2015097829 A JP2015097829 A JP 2015097829A JP 2015218166 A5 JP2015218166 A5 JP 2015218166A5
Authority
JP
Japan
Prior art keywords
crystalline form
expressed
isoquinoline
carbonitrile
dioxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015097829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015218166A (ja
JP6523782B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015218166A publication Critical patent/JP2015218166A/ja
Publication of JP2015218166A5 publication Critical patent/JP2015218166A5/ja
Application granted granted Critical
Publication of JP6523782B2 publication Critical patent/JP6523782B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015097829A 2014-05-15 2015-05-13 新規な結晶性化合物 Expired - Fee Related JP6523782B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461993693P 2014-05-15 2014-05-15
US61/993,693 2014-05-15
US201562138037P 2015-03-25 2015-03-25
US62/138,037 2015-03-25

Publications (3)

Publication Number Publication Date
JP2015218166A JP2015218166A (ja) 2015-12-07
JP2015218166A5 true JP2015218166A5 (enExample) 2018-06-21
JP6523782B2 JP6523782B2 (ja) 2019-06-05

Family

ID=53276206

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015097829A Expired - Fee Related JP6523782B2 (ja) 2014-05-15 2015-05-13 新規な結晶性化合物

Country Status (21)

Country Link
US (1) US9920043B2 (enExample)
EP (1) EP3143019B1 (enExample)
JP (1) JP6523782B2 (enExample)
KR (1) KR101817889B1 (enExample)
CN (1) CN106459025B (enExample)
AU (1) AU2015260906B2 (enExample)
CA (1) CA2891398C (enExample)
CY (1) CY1123826T1 (enExample)
DK (1) DK3143019T3 (enExample)
ES (1) ES2845639T3 (enExample)
HU (1) HUE052692T2 (enExample)
IL (1) IL248918A0 (enExample)
MX (1) MX371014B (enExample)
PL (1) PL3143019T3 (enExample)
PT (1) PT3143019T (enExample)
RU (1) RU2698194C2 (enExample)
SG (1) SG11201608320QA (enExample)
SI (1) SI3143019T1 (enExample)
TW (1) TWI553007B (enExample)
WO (1) WO2015173684A1 (enExample)
ZA (1) ZA201606796B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950390C (en) * 2014-05-30 2020-09-22 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0089139A2 (en) 1982-03-16 1983-09-21 Beecham Group Plc Antibiotics, their preparation and use
US4489075A (en) * 1982-05-15 1984-12-18 Pfizer Inc. Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP1636167A2 (en) 2003-06-10 2006-03-22 SmithKline Beecham Corporation 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors
US7816372B2 (en) * 2003-08-22 2010-10-19 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
MX2010006972A (es) * 2007-12-21 2010-08-26 Ligand Pharm Inc Moduladores selectivos de receptores de andrógenos (sarm) y usos de los mismos.
MY176727A (en) * 2012-12-03 2020-08-20 Pfizer Selective androgen receptor modulators

Similar Documents

Publication Publication Date Title
RU2017142958A (ru) Кристаллы азабициклического соединения
JP2017531020A5 (enExample)
JP2015512951A5 (enExample)
JP2018520205A5 (enExample)
JP2015511958A5 (enExample)
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
JP2018024682A5 (enExample)
WO2012042539A3 (en) 3 -azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders
MX2017013483A (es) Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1).
JP2013543867A5 (enExample)
JP2012521994A5 (enExample)
JP2012526808A5 (enExample)
JP2020519654A5 (enExample)
JP2016510768A5 (enExample)
JP2013522325A5 (enExample)
JP2014530818A5 (enExample)
JP2012533550A5 (enExample)
JP2018524342A5 (enExample)
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
JP2019520321A5 (enExample)
JP2010514725A5 (enExample)
SI2197841T1 (sl) Spojine, ki vsebujejo gvanidin, uporabne kot antagonisti muskarinskih receptorjev
JP2020502224A5 (enExample)
JP2015516425A5 (enExample)
JP2015218166A5 (enExample)